^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Alunbrig (brigatinib)

    i
    Company:
    Takeda
    Drug class:
    EGFR inhibitor, ALK inhibitor
    Related drugs:
    Apply
    Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (NRG-LU003) (NCT03737994)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/25/2019
    Primary completion :
    07/21/2021
    Completion :
    12/02/2025
    MET
    |
    ALK positive • MET amplification • ALK rearrangement
    |
    cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)
    A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (ALTA-3) (NCT03596866)
    Phase 3
    Takeda
    Completed
    Last update posted :
    02/19/2025
    Initiation :
    04/19/2019
    Primary completion :
    02/27/2024
    Completion :
    09/12/2024
    ALK
    |
    ALK positive • ALK rearrangement
    |
    Xalkori (crizotinib) • Alecensa (alectinib) • Alunbrig (brigatinib)
    Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) (NCT04374305)
    Phase 2
    Scott R. Plotkin, MD, PhD
    Active, not recruiting
    Last update posted :
    11/18/2024
    Initiation :
    06/20/2020
    Primary completion :
    12/01/2029
    Completion :
    12/01/2030
    NF2
    |
    Nerlynx (neratinib) • Alunbrig (brigatinib)
    Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping (NCT04318938)
    Phase 2
    Institut für Klinische Krebsforschung IKF GmbH ...
    Active, not recruiting
    Last update posted :
    10/14/2024
    Initiation :
    03/30/2020
    Primary completion :
    01/16/2026
    Completion :
    01/16/2026
    ALK • TP53
    |
    TP53 mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation
    |
    Alunbrig (brigatinib)
    Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (PIKACHU) (NCT04322890)
    Phase 2
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/16/2020
    Primary completion :
    12/24/2026
    Completion :
    12/24/2027
    EGFR • BRAF • ALK • ROS1
    |
    EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation
    |
    cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)
    Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC (NCT04227028)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    05/07/2024
    Initiation :
    03/09/2020
    Primary completion :
    11/01/2024
    Completion :
    11/01/2024
    ALK
    |
    ALK rearrangement
    |
    Avastin (bevacizumab) • Alunbrig (brigatinib) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (CUBIK) (NCT04223596)
    Phase 2
    Fundación GECP
    Active, not recruiting
    Last update posted :
    05/06/2024
    Initiation :
    05/04/2020
    Primary completion :
    12/30/2024
    Completion :
    04/15/2025
    ALK
    |
    ALK positive • ALK rearrangement
    |
    Alunbrig (brigatinib)
    Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) (IFCT-2101 MASTERPROTOCOL ALK) (NCT05200481)
    Phase 2
    Intergroupe Francophone de Cancerologie Thoracique
    Recruiting
    Last update posted :
    03/07/2024
    Initiation :
    05/18/2022
    Primary completion :
    04/01/2025
    Completion :
    10/01/2028
    ALK
    |
    ALK rearrangement
    |
    carboplatin • pemetrexed • Alunbrig (brigatinib)
    A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC) (Brilliant) (NCT05721950)
    Phase N/A
    Takeda
    Recruiting
    Last update posted :
    03/04/2024
    Initiation :
    01/17/2024
    Primary completion :
    12/01/2024
    Completion :
    12/31/2026
    ALK
    |
    ALK rearrangement
    |
    Alunbrig (brigatinib)
    Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project) (GALILEO) (NCT06234579)
    Phase N/A
    Fondazione Policlinico Universitario Agostino G...
    Recruiting
    Last update posted :
    01/31/2024
    Initiation :
    07/12/2021
    Primary completion :
    03/31/2024
    Completion :
    07/31/2026
    ALK
    |
    Alecensa (alectinib) • Lorbrena (lorlatinib) • Alunbrig (brigatinib)
    Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer (NCT05100069)
    Phase N/A
    Takeda
    Recruiting
    Last update posted :
    10/18/2023
    Initiation :
    11/01/2021
    Primary completion :
    05/31/2026
    Completion :
    05/31/2026
    ALK
    |
    ALK positive • ALK fusion
    |
    Alunbrig (brigatinib)
    A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea (NCT04592523)
    Phase N/A
    Takeda
    Recruiting
    Last update posted :
    10/12/2023
    Initiation :
    09/05/2019
    Primary completion :
    08/26/2026
    Completion :
    08/26/2026
    ALK
    |
    ALK positive
    |
    Alunbrig (brigatinib)
    The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) (NCT04591431)
    Phase 2
    Fondazione per la Medicina Personalizzata
    Active, not recruiting
    Last update posted :
    10/03/2023
    Initiation :
    10/07/2020
    Primary completion :
    12/01/2024
    Completion :
    06/01/2025
    PD-L1 • BRAF
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • everolimus • lapatinib • Alecensa (alectinib) • Perjeta (pertuzumab) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Talzenna (talazoparib) • Piqray (alpelisib) • Retevmo (selpercatinib) • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Pemazyre (pemigatinib) • ipatasertib (RG7440) • Tepmetko (tepotinib) • itacitinib (INCB039110)
    A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY (NCT05735327)
    Phase N/A
    Takeda
    Recruiting
    Last update posted :
    09/04/2023
    Initiation :
    05/22/2023
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    ALK
    |
    ALK positive
    |
    Alunbrig (brigatinib)
    A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2) (NCT03535740)
    Phase 2
    Ariad Pharmaceuticals
    Active, not recruiting
    Last update posted :
    08/25/2023
    Initiation :
    01/31/2019
    Primary completion :
    09/30/2020
    Completion :
    06/28/2024
    ALK
    |
    ALK rearrangement
    |
    Alecensa (alectinib) • Zykadia (ceritinib) • Alunbrig (brigatinib)
    A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC) (NCT04887519)
    Phase N/A
    Takeda
    Completed
    Last update posted :
    04/17/2023
    Initiation :
    12/30/2020
    Primary completion :
    03/31/2023
    Completion :
    03/31/2023
    ALK
    |
    ALK positive
    |
    Alunbrig (brigatinib)
    A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors (NCT03420742)
    Phase 1
    Takeda
    Completed
    Last update posted :
    01/27/2023
    Initiation :
    06/26/2019
    Primary completion :
    03/24/2020
    Completion :
    04/29/2021
    ROS1
    |
    ALK positive • ROS1 positive
    |
    Alunbrig (brigatinib) • midazolam hydrochloride
    A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions. (NCT05361564)
    Phase 2
    Yonsei University
    Not yet recruiting
    Last update posted :
    05/04/2022
    Initiation :
    06/01/2022
    Primary completion :
    06/01/2024
    Completion :
    06/01/2024
    ALK
    |
    ALK rearrangement
    |
    Alunbrig (brigatinib)
    Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers (NCT03868423)
    Phase 2
    Sameek Roychowdhury
    Withdrawn
    Last update posted :
    02/18/2022
    Initiation :
    03/20/2019
    Primary completion :
    11/20/2020
    Completion :
    12/30/2021
    ALK • ROS1
    |
    ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation
    |
    Alunbrig (brigatinib)
    Retrospective, Observational, Multi-center Study Evaluating the Efficacy and Tolerance of Brigatinib in the Management of Rearranged CBNPC ROS1 (BRIGAROS) (NCT04718012)
    Phase N/A
    Centre Hospitalier Intercommunal Creteil
    Completed
    Last update posted :
    11/22/2021
    Initiation :
    03/17/2021
    Primary completion :
    10/17/2021
    Completion :
    10/17/2021
    ROS1
    |
    Alunbrig (brigatinib)
    ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants (NCT02737501)
    Phase 3
    Ariad Pharmaceuticals
    Completed
    Last update posted :
    08/20/2021
    Initiation :
    05/26/2016
    Primary completion :
    07/28/2020
    Completion :
    01/29/2021
    ALK
    |
    ALK rearrangement
    |
    Xalkori (crizotinib) • Alunbrig (brigatinib)
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) (NCT01449461)
    Phase 1/2
    Ariad Pharmaceuticals
    Completed
    Last update posted :
    08/17/2021
    Initiation :
    09/20/2011
    Primary completion :
    11/16/2015
    Completion :
    02/18/2020
    ALK • ROS1
    |
    EGFR mutation • EGFR T790M • ALK rearrangement • ROS1 fusion • ALK-ROS1 fusion
    |
    Alunbrig (brigatinib)
    A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib (ALTA) (NCT02094573)
    Phase 2
    Ariad Pharmaceuticals
    Completed
    Last update posted :
    03/15/2021
    Initiation :
    06/04/2014
    Primary completion :
    02/29/2016
    Completion :
    02/27/2020
    ALK
    |
    ALK positive • ALK rearrangement
    |
    Xalkori (crizotinib) • Alunbrig (brigatinib)
    Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma (NCT03719898)
    Phase 2
    Fox Chase Cancer Center
    Withdrawn
    Last update posted :
    01/05/2021
    Initiation :
    12/06/2018
    Primary completion :
    03/18/2020
    Completion :
    06/16/2020
    CD4
    |
    Alunbrig (brigatinib)
    An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer (NCT02784158)
    Phase N/A
    Ariad Pharmaceuticals
    No Longer Available
    Last update posted :
    02/06/2018
    ALK
    |
    ALK rearrangement
    |
    Alunbrig (brigatinib)